Download PDF
Thromb Haemost 2014; 112(04): 781-788
DOI: 10.1160/TH14-01-0092
Cardiovascular Biology and Cell Signalling
Schattauer GmbH

Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation

Vanessa Roldán
1   Centro Regional de Hemodonación, Hematology and Medical Oncology Unit, Hospital Universitario Morales Meseguer, IMIB, Murcia, Spain
,
Ana Belen Arroyo
1   Centro Regional de Hemodonación, Hematology and Medical Oncology Unit, Hospital Universitario Morales Meseguer, IMIB, Murcia, Spain
,
Sallam Salloum-Asfar
1   Centro Regional de Hemodonación, Hematology and Medical Oncology Unit, Hospital Universitario Morales Meseguer, IMIB, Murcia, Spain
,
Sergio Manzano-Fernández
2   Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, University of Murcia, IMIB, Murcia, Spain
,
Nuria García-Barberá
1   Centro Regional de Hemodonación, Hematology and Medical Oncology Unit, Hospital Universitario Morales Meseguer, IMIB, Murcia, Spain
,
Francisco Marín
2   Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, University of Murcia, IMIB, Murcia, Spain
,
Vicente Vicente
1   Centro Regional de Hemodonación, Hematology and Medical Oncology Unit, Hospital Universitario Morales Meseguer, IMIB, Murcia, Spain
,
Rocío González-Conejero   *
1   Centro Regional de Hemodonación, Hematology and Medical Oncology Unit, Hospital Universitario Morales Meseguer, IMIB, Murcia, Spain
,
Constantino Martínez   *
1   Centro Regional de Hemodonación, Hematology and Medical Oncology Unit, Hospital Universitario Morales Meseguer, IMIB, Murcia, Spain
› Author Affiliations Financial support: This work was supported by research grants from Instituto Carlos III and Fondo Europeo de Desarrollo Regional (FEDER) (PI11/00566, PI11/1256, and Red RIC RD12/0042/0050) and Fundación Española de Trombosis y Hemostasia. CM is an investigator from Fundación para la Formación e Investigación Sanitarias de la Región de Murcia. SMF has received funding for research from Sociedad Española de Cardiología.
Further Information

Publication History

Received: 29 January 2014

Accepted after major revision: 21 May 2014

Publication Date:
21 November 2017 (online)

    Permissions and Reprints

Summary

There are few biomarkers able to forecast new thrombotic events in patients with AF. In this framework, microRNAs have emerged as critical players in cardiovascular biology. In particular, miR-146a-5p is recognised as an important negative regulator of inflammation. This study aims to evaluate the prognostic role and biological effect of functional MIR146A polymorphisms, rs2431697 and rs2910164, in non-valvular atrial fibrillation (AF) patients under oral anticoagulation. We studied 901 patients with permanent/paroxysmal AF stabilized for at least six months. Patients were followed-up for two years and adverse cardiovascular events (ACE) were recorded. In vitro studies were performed in monocytes from healthy homozygous for the two genotypes of rs2431697. Rs2910164 had no association with ACE. However, multivariate analysis (adjusted by CHA2DS2–VASc score) revealed that rs2431697TT was associated with adverse cardiovascular events [HR: 1.64 (1.09–2.47); p=0.017]. The predictive value of usefulness of the CHA2DS2–VASc+IL6+rs2431697 for predicting ACE, was statistically better than that predicted by CHA2DS2–VASc+IL6. Functional studies showed that after 24 hours incubation, monocytes from CC individuals showed a 65 % increase in miR-146a-5p levels, while TT individuals only showed a 28 % increase. Indeed, after 24 hours of LPS activation, TT monocytes showed a higher increase in IL6 mRNA expression than CC (52 % vs 26 %). Our study established MIR146A rs2431697 as a prognostic biomarker for ACE in anticoagulated AF patients. These data suggest that TT individuals, when submitted to an inflammatory stress, may be prone to a highest pro-inflammatory state due, in part, to lower levels of miR-146a-5p.

Keywords

Atrial fibrillation - mir-146a-5p - inflammation - cardiovascular event

* RGC and CM share senior authorship.


 

  • References

  • 1 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
    CrossrefPubMedGoogle Scholar
  • 2 Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009; 373: 155-166.
    CrossrefPubMedGoogle Scholar
  • 3 Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007; 50: 2021-2028.
    CrossrefPubMedGoogle Scholar
  • 4 Patel P, Dokainish H, Tsai P. et al. Update on the association of inflammation and atrial fibrillation. J Cardiovasc Electrophysiol 2010; 21: 1064-1070.
    CrossrefPubMedGoogle Scholar
  • 5 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
    CrossrefPubMedGoogle Scholar
  • 6 Gage BF, Waterman AD, Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864-2870.
    CrossrefPubMedGoogle Scholar
  • 7 Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe?. Thromb Haemost 2010; 104: 45-48.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
    CrossrefPubMedGoogle Scholar
  • 9 Roldan V, Marin F, Diaz J. et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost 2012; 10: 1500-1507.
    CrossrefPubMedGoogle Scholar
  • 10 MacCallum PK, Rudnicka AR, Rumley A. et al. Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarction. Br J Haematol 2004; 127: 448-450.
    CrossrefPubMedGoogle Scholar
  • 11 Pardali E, Waltenberger J. Monocyte function and trafficking in cardiovascular disease. Thromb Haemost 2012; 108: 804-811.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Jover E, Marin F, Roldan V. et al. Atherosclerosis and thromboembolic risk in atrial fibrillation: Focus on peripheral vascular disease. Ann Med 2013; 45: 274-290.
    CrossrefPubMedGoogle Scholar
  • 13 Depta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes. Thromb Haemost 2010; 104: 657-663.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Li J, Solus J, Chen Q. et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010; 7: 438-444.
    CrossrefPubMedGoogle Scholar
  • 15 Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012; 60: 2263-2270.
    CrossrefPubMedGoogle Scholar
  • 16 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
    CrossrefPubMedGoogle Scholar
  • 17 Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
    CrossrefPubMedGoogle Scholar
  • 18 Wang Z, Lu Y, Yang B. MicroRNAs and atrial fibrillation: new fundamentals. Cardiovasc Res 2011; 89: 710-721.
    CrossrefPubMedGoogle Scholar
  • 19 Martin K, O’Sullivan JF, Caplice NM. New therapeutic potential of microRNA treatment to target vulnerable atherosclerotic lesions and plaque rupture. Curr Opin Cardiol 2011; 26: 569-575.
    CrossrefPubMedGoogle Scholar
  • 20 Taganov KD, Boldin MP, Chang KJ. et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481-12486.
    CrossrefPubMedGoogle Scholar
  • 21 Jin J, Samuvel DJ, Zhang X. et al. Coactivation of TLR4 and TLR2/6 coordinates an additive augmentation on IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cells. Mol Immunol 2011; 49: 423-432.
    CrossrefPubMedGoogle Scholar
  • 22 Lofgren SE, Frostegard J, Truedsson L. et al. Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes Immun 2012; 13: 268-274.
    CrossrefPubMedGoogle Scholar
  • 23 Jeon YJ, Kim OJ, Kim SY. et al. Association of the miR-146a, miR-149, miR-196a2, and miR-499 polymorphisms with ischemic stroke and silent brain infarction risk. Arterioscler Thromb Vasc Biol 2013; 33: 420-430.
    CrossrefPubMedGoogle Scholar
  • 24 Ramkaran P, Khan S, Phulukdaree A. et al. miR-146a Polymorphism Influences Levels of miR-146a, IRAK-1, and TRAF-6 in Young Patients with Coronary Artery Disease. Cell Biochem Biophys 2014; 68: 259-266.
    CrossrefPubMedGoogle Scholar
  • 25 Jauch EC, Saver JL, Adams Jr., HP. et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870-947.
    CrossrefPubMedGoogle Scholar
  • 26 Thygesen K, Alpert JS, Jaffe AS. et al. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551-2567.
    CrossrefPubMedGoogle Scholar
  • 27 McMurray JJ, Adamopoulos S, Anker SD. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847.
    CrossrefPubMedGoogle Scholar
  • 28 Pencina MJ, D’Agostino Sr., RB, D’Agostino Jr., RB. et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.
    CrossrefPubMedGoogle Scholar
  • 29 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
    CrossrefPubMedGoogle Scholar
  • 30 Seneviratne AN, Sivagurunathan B, Monaco C. Toll-like receptors and macrophage activation in atherosclerosis. Clin Chim Acta 2012; 413: 3-14.
    CrossrefPubMedGoogle Scholar
  • 31 Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from patho-physiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138.
    CrossrefPubMedGoogle Scholar
  • 32 Roldan V, Marin F, Muina B. et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011; 57: 2496-2504.
    CrossrefPubMedGoogle Scholar
  • 33 Harley JB, Alarcon-Riquelme ME. et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008; 40: 204-210.
    CrossrefPubMedGoogle Scholar
  • 34 Luo X, Yang W, Ye DQ. et al. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet 2011; 7: e1002128.
    CrossrefPubMedGoogle Scholar
  • 35 Chen HF, Hu TT, Zheng XY. et al. Association between miR-146a rs2910164 polymorphism and autoimmune diseases susceptibility: a meta-analysis. Gene 2013; 521: 259-264.
    CrossrefPubMedGoogle Scholar
  • 36 Jazdzewski K, Murray EL, Franssila K. et al. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA 2008; 105: 7269-7274.
    CrossrefPubMedGoogle Scholar
  • 37 Xu Y, Li L, Xiang X. et al. Three common functional polymorphisms in microRNA encoding genes in the susceptibility to hepatocellular carcinoma: A systematic review and meta-analysis. Gene 2013; 527: 584-593.
    CrossrefPubMedGoogle Scholar
  • 38 Wang X, Ha T, Liu L. et al. Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury. Cardiovasc Res 2013; 97: 432-442.
    CrossrefPubMedGoogle Scholar
  • 39 Nahid MA, Satoh M, Chan EK. Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling. J Immunol 2011; 186: 1723-1734.
    CrossrefPubMedGoogle Scholar
  • 40 Stachon P, Missiou A, Walter C. et al. Tumor necrosis factor receptor associated factor 6 is not required for atherogenesis in mice and does not associate with atherosclerosis in humans. PLoS One 2010; 5: e11589.
    CrossrefPubMedGoogle Scholar
  • 41 Zhao JL, Rao DS, O’Connell RM. et al. MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice. Elife 2013; 2: e00537.
    CrossrefPubMedGoogle Scholar
  • 42 Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343-1345.
    CrossrefPubMedGoogle Scholar
  • 43 Ozaydin M, Varol E, Aslan SM. et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006; 97: 1490-1493.
    CrossrefPubMedGoogle Scholar
  • 44 Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 2012; 148: 1172-1187.
    CrossrefPubMedGoogle Scholar
  • 45 Nahid MA, Pauley KM, Satoh M. et al. miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity. J Biol Chem 2009; 284: 34590-34599.
    CrossrefPubMedGoogle Scholar
  • 46 Cheng HS, Sivachandran N, Lau A. et al. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med 2013; 5: 1017-1034.
    CrossrefPubMedGoogle Scholar
  • 47 Wan Y, Heneghan C, Perera R. et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 1: 84-91.
    CrossrefPubMedGoogle Scholar